January 03, 2025

Surgeon General Issues Advisory on Alcohol, Cancer Link

Of all breast cancer cases in the U.S., 16.4% are directly linked to alcohol consumption.

Conexiant

December 19, 2024

Mesenchymal Cell Therapy Approved for Steroid-Refractory Acute GVHD

The U.S. Food and Drug Administration (FDA) recently approved remestemcel-L-rknd (Ryoncil), an allogeneic bone marrow–derived mesenchymal stromal cell therapy for steroid-refractory acute graft-vs-hos...

The ASCO Post

December 16, 2024

Cosibelimab-ipdl Approved by FDA for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

The U.S. Food and Drug Administration (FDA) recently approved cosibelimab-ipdl (Unloxcyt), a PD-L1–blocking antibody, for adults with metastatic or locally advanced cutaneous squamous cell carcinoma w...

The ASCO Post

December 09, 2024

FDA Approves Novel Companion Diagnostic Assay

The U.S. Food and Drug Administration (FDA) has approved a novel companion diagnostic assay to help identify patients with cancer who may benefit from targeted therapies.

The ASCO Post

July 18, 2023

First Oral Medication to Treat Moderate-to-Severe Crohn’s Disease Earns FDA Approval

Upadacitinib, the first oral treatment for Crohn's disease, has been approved by the Food and Drug Administration. The approval came in part through a Mount Sinai-led clinical trial that showed it to be more efficacious than placebo.

Mount Sinai New York

June 21, 2023

FDA Launches Pilot Program to Help Reduce Risks Associated With Using Laboratory Developed Tests to Identify Cancer Biomarkers

The U.S. Food and Drug Administration (FDA) announced a new voluntary pilot program to help physicians select safe and effective cancer treatments, with guidance on in vitro companion diagnostic tests...

The ASCO Post

November 17, 2023

FDA Approves Capivasertib With Fulvestrant for Breast Cancer

On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or m...

The ASCO Post

August 29, 2023

FDA Approves Luspatercept-aamt as First-Line Treatment for Adult Patients With Lower-Risk MDS and Anemia Who May Require Transfusions

On August 28, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) to treat anemia in adult patients with very low– to intermediate-risk myelodysplastic syndromes (MDS) wh...

The ASCO Post

August 05, 2024

FDA Grants Accelerated Approval to T-Cell Therapy for Unresectable or Metastatic Synovial Sarcoma

On August 2, the FDA granted accelerated approval to afamitresgene autoleucel (Tecelra), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for a...

The ASCO Post